Prior to founding Inhibikase, Dr. Werner served as Vice President of Research at Celtaxsys, Inc., a cell-free immunotherapeutics company. From September 1996 until June 2007, Dr. Werner was a Head of the Laboratory of Molecular Biophysics at The Rockefeller University and departed the University at the rank of Associate Professor. While at The Rockefeller University, Dr. Werner focused on developing more complete understandings of mechanisms of human disease in immunology, oncology, and infectious disease.
Dr. Werner is the author or co-author of more than 70 research articles, reviews, and book chapters and has given lectures on his research work on more than 150 occasions throughout the world. He is the recipient of numerous private and public research grants totaling more than $10 million and of several awards, including the Young Investigator Award from the Sidney Kimmel Cancer Foundation, the Research Chair from the Brain Tumor Society, and a $1 million Distinguished Young Scholars in Medical Research award from the W. M. Keck Foundation. Dr. Werner received his PhD in Chemistry from the University of California, Berkeley and his BS in Biochemistry from the University of Southern California.
Mr. Frattaroli has served as our Chief Financial Officer since April 2018. Mr. Frattaroli is a certified public accountant with more than 15 years of experience in public company filings and compliance for Nasdaq and OTC Markets companies. He founded Flagship Consulting, Inc. in January 2010, through which he has provided chief financial officer and consulting services for several emerging biopharmaceutical and medical device companies, with responsibilities that included capital formation, deal structuring, and assisting private companies in their transition to becoming publicly traded SEC registrants. He has also served as an independent consultant to Danforth Advisors LLC since July 2015, providing interim chief financial officer and strategic advisory services to emerging public and private biotechnology and biopharmaceutical clients of Danforth Advisors LLC. Mr. Frattaroli received his BS in Accounting from Salem State University and was certified as a public accountant while employed by Ernst & Young, LLP.
Dan acts as the Company’s controller through his own company Startup Personnel, LLC.
Dr. Kelly is is a 30-year pharmaceutical industry veteran and has served as a member of the board of directors of Cardax, Inc. since June 2014. He is a founder of Kelly Pharma Research Consulting, LLC and has served as its President since January 2010. From June 2010 to July 2017, he held several positions at CoMentis, including most recently President and CEO. From July 2002 to December 2009, he served as Vice President of Medicinal Chemistry at Boehringer Ingelheim Pharmaceuticals, Inc., where he, developed processes for the RAMP drug discovery program.
Voisin Life Science Consulting is a regulatory affairs professional firm with extensive product development experience in the pharmaceutical and biotechnology industries as well as regulatory experience at the USFDA and EMA. The company has helped to guide development programs for small molecules and biologics through all phases of regulatory review.
Dr. Singh is an expert in chemical process research and development from lead optimization to launch, technology transfer, and API manufacturing. From 2001 to 2011, he served various roles at Sunovion Pharmaceuticals Inc. and its predecessor, Sepracor Inc., including as a director of chemical process research, and has served as a chemistry, manufacturing, and control consultant for AVEO Oncology, RestorGenex Corporation, Verastem Oncology, and Syner-G Pharma Consulting, LLC. Dr. Singh received his doctoral degree from the Indian Institute of Technology in 1991 and was a postdoctoral fellow at The Ohio State University. Dr. Singh establishes and manages the commercial process, global outsourcing, and global vendor management as well as participates in all aspects of the drafting and review of regulatory documents, from IND to NDA.
Dr. Rush is an experienced veteran of the pharmaceutical industry with more than 30 years of experience working in the United Kingdom and U.S. for small and large pharmaceutical companies and contract research organizations, and is now based in the Greater Boston area. His major career focus has been on preclinical research and development, safety assessment, and the translation of discovery research molecules into clinical development. He has contributed to more than 20 IND, CTA, and product license submissions and approved drugs, including nicardipine (Cardene), ranolazine (Ranexa), Foscan, and zileuton (Zyflo CR). He has been a principal of Allon Preclinical Consulting, LLC since 2015. From March 2012 to December 2014, he was Vice President, Preclinical Development for Idenix Pharmaceuticals, Inc., a wholly owned subsidiary of Merck & Company, Inc., where he managed the DMPK, toxicology, and discovery research that led to the identification of lead molecules to treat Hepatitis C virus. His work has spanned numerous therapeutic areas, including anti-inflammatory, anti-allergy, arthritis, anti-infectives, CNS, cardiovascular, oncology, genitourinary, and anti-hyperlipidaemics. He received his B.Sc. and Ph.D. degrees in Biochemistry from the University of Surrey in the United Kingdom.
Merrill M. Kraines is a partner in the Health Sciences Department of Pepper Hamilton LLP, resident in the New York office. Mr. Kraines is primarily engaged in corporate, securities, and mergers and acquisitions matters. He leads the life sciences, technology, and emerging growth practices in New York. Mr. Kraines represents many life sciences companies, including biotechnology, therapeutic, diagnostic, and medical device companies. He has also represented or been involved in transactions concerning a variety of other growth companies in all phases of business and finance in many industries, including software, Internet, health care, IT, alternative energy, financial services, IT consulting, educational publishing, entertainment, office products, advertising, telecommunications, paper, and many other companies. These companies have ranged from start-ups to large public concerns.